Insight on What Matters - So You Can Transform Your Business.
In recent years the modern work environment has rapidly evolved with companies of all shapes and sizes working in multiple locations and often collaborating closely with a myriad of partners and organizations around the globe.
In advance of the webinar, we sat down with Javier to discuss some of the nuances of structuring earnouts in M&A transactions and the implications for both the buyer and seller.
Using a full-featured virtual data room to facilitate the due diligence process can reduce or eliminate many of the common M&A pitfalls that often cause deals to unravel.
What follows are eight key factors that we believe are critical in the process of taking a life sciences company from founding to exit.
In advance of the web panel discussion, we sat down with Linda Pullan to learn a little more about bispecifics and what you can expect to learn from the discussion.
There are a growing number of start-ups that are applying AI to drug discovery research, including Berg, Numerate, twoXAR and Atomwise.
The recent advent of genome-editing technologies has enabled a new paradigm in which the sequence of the human genome can be precisely manipulated to achieve a therapeutic effect.
The Meltdown and Spectre vulnerabilities are consequences of a modern CPU performance feature called speculative execution.
The Trial Master File (TMF) is one of the most important deliverables of a clinical trial because it’s the basis for inspection.
Fierce Biotech's John Carroll reports on a new analyst report from Silicon Valley Bank, describing the ongoing trend of Big Pharma outsourcing its R&D to Biotechs through corporate venture investments.
Blog